EnBio Holdings Inc is a leading company that upholds strong values and a comprehensive corporate philosophy. The company is known for its commitment to innovation, sustainability, and growth. EnBio Holdings Inc places great importance on integrity, transparency, and accountability in all aspects of its operations. With a customer-centric approach, the company aims to provide exceptional products and services while fostering long-term relationships with clients. EnBio Holdings Inc believes in fostering a collaborative and inclusive work environment, promoting employee development, and giving back to the community. With a focus on excellence, EnBio Holdings Inc constantly strives to exceed expectations and make a positive impact in the industry.

EnBio Holdings Inc is primarily present in Japan and Asia-Pacific region.

EnBio Holdings Inc has achieved significant milestones throughout its history. The company successfully introduced innovative products to the market, revolutionizing the industry. EnBio Holdings Inc also expanded its global presence, establishing a strong presence in key international markets. Furthermore, the company consistently delivered strong financial performance and experienced significant growth in its revenue and market share. With its continued dedication to research and development, EnBio Holdings Inc has also received several prestigious awards and accolades for its groundbreaking contributions in the field. These achievements demonstrate EnBio Holdings Inc's commitment to excellence and position it as a prominent leader in the industry.

EnBio Holdings Inc. is a prominent company in the field of biotechnology. Founded in [year], the company has been actively involved in research and development to revolutionize the healthcare industry. EnBio Holdings Inc. focuses on creating innovative solutions for various medical conditions and improving overall patient care. With their dedicated team of scientists and experts, the company has made significant strides in developing groundbreaking therapies and drugs. EnBio Holdings Inc. has also collaborated with renowned institutions to accelerate advancements in biotechnology. Their commitment to innovation and improving global health makes them a leader in the biotech sector.

The main competitors of EnBio Holdings Inc in the market include XYZ Company, ABC Corporation, and DEF Enterprises. These companies offer similar products and services and compete with EnBio Holdings Inc in terms of market share and customer base. However, EnBio Holdings Inc differentiates itself through its innovative solutions, strategic partnerships, and strong brand reputation. With its unique offerings, EnBio Holdings Inc aims to maintain a competitive edge in the market and continue its growth trajectory.

EnBio Holdings Inc is primarily active in the biotechnology and healthcare industries.

The business model of EnBio Holdings Inc is centered around the development and commercialization of innovative medical technologies and products. Through extensive research and collaboration, EnBio aims to provide solutions that improve healthcare outcomes and enhance patient well-being. By leveraging their expertise in areas such as regenerative medicine, biomaterials, and medical devices, EnBio strives to create value for healthcare professionals and patients alike. With a focus on continual innovation and a commitment to meeting market needs, EnBio Holdings Inc aims to establish itself as a leading player in the healthcare industry.

EnBio Holdings KGV ir 6,75.

EnBio Holdings KUV ir 0,50.

AlleAktien kvalitātes vērtējums EnBio Holdings ir 4/10.

EnBio Holdings apgrozījums ir 9,58 miljardi JPY.

EnBio Holdings peļņa ir 708,76 milj. JPY.

EnBio Holdings Inc. is an innovative company that works with a wide range of products and services in the fields of bioscience, medicine, and environmental technology. The company operates globally and collaborates closely with research and development companies to reduce the environmental impacts of industrial, medical, and everyday products. The business model of EnBio Holdings Inc. is based on three key areas: bioscience, medicine, and environmental technology. All of these areas are interconnected and dedicated to developing innovative solutions based on scientific knowledge and technological advancements. The first business area of EnBio Holdings Inc. is bioscience. In this field, the company collaborates closely with pharmaceutical, chemical, and biotechnology companies to develop new technologies and materials that contribute to minimizing the environmental impacts of products and processes. This includes innovative technologies such as biodegradable materials and environmentally friendly production techniques. The second business area of EnBio Holdings Inc. is medicine. In this field, the company works closely with medical facilities and research institutions to develop innovative medical products and technologies. These products and technologies range from medical devices to pharmaceuticals based on scientific research and development. The third business area of EnBio Holdings Inc. is environmental technology. Here, the company develops innovative technologies and solutions to minimize the industry's impact on the environment. The company collaborates closely with companies and institutions to develop environmentally friendly technologies and solutions for the industry. This includes technologies for reducing CO2 emissions and also technologies for more environmentally friendly waste management. EnBio Holdings Inc. offers a wide range of products and services for all three business areas. The company's products and services include: -Biocompatible materials for bioscience -Medical devices and pharmaceuticals for medicine -Environmental technology for the industry The company also provides technical solutions and consulting services to assist customers in implementing its innovative technologies and solutions. Overall, the business model of EnBio Holdings Inc. is focused on science-based, environmentally friendly, and sustainable development. The company collaborates closely with customers and research institutions to develop innovative solutions for bioscience, medicine, and environmental technology.

EnBio Holdings izmaksā dividendes 8,00 JPY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt EnBio Holdings vai uzņēmums nedod dividendes.

EnBio Holdings ISIN ir JP3169730003.

EnBio Holdings WKN ir A1XFCH.

EnBio Holdings simbols ir 6092.T.

Pēdējo 12 mēnešu laikā EnBio Holdings maksāja dividendes 8,00 JPY apmērā. Tas atbilst aptuveni 1,33 % dividendes ražībai. Nākamajos 12 mēnešos EnBio Holdings plāno maksāt dividendes 8,00 JPY apmērā.

EnBio Holdings pašreizējā dividendu rentabilitāte ir 1,33 %.

EnBio Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos aprīlis, aprīlis, aprīlis, aprīlis.

EnBio Holdings pēdējo 3 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 8,00 JPY. Tas atbilst dividendes ražībai 1,33 %.

EnBio Holdings tiek piešķirts nozarei "Industrija".

Lai saņemtu pēdējo dividendu EnBio Holdings apmērā 8 JPY, kas tika izmaksāta 1.06.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 28.03.2024..

Pēdējās dividendes izmaksa notika 1.06.2024..

Gadā 2023, EnBio Holdings izmaksāja 8 JPY dividendes.

EnBio Holdings dividendes tiek izmaksātas JPY.